Please login to the form below

Not currently logged in
Email:
Password:

Loxo

This page shows the latest Loxo news and features for those working in and with pharma, biotech and healthcare.

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

The pharma giant picked up the oral RET inhibitor after acquiring Loxo Oncology for $8bn in January 2019.

Latest news

More from news
Approximately 7 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    This is the first US product approval for Loxo Oncology and its marketing partner Bayer, becoming the second company to get FDA backing for a drug that treats cancer based on ... NTRK fusions are rare – Loxo estimates that there are around 2, 500 to 3,

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...